A-TAP - Arthritis Therapy Acceleration Programme
The Arthritis Therapy Acceleration Programme (A-TAP) is an exciting new £7M concept funded by the Kennedy Trust for Rheumatology Research. It brings together the Universities of Birmingham and Oxford and seven NHS partners and is supported by our access to over 7million patients. The initiative is aiming to support and develop novel treatments for arthritis based on the underlying causes of inflammatory disease.
This ambition is facilitated by our innovative new approach to translational inflammation research through our application of unique rigorous signal seeking experimental medicine studies leading to rapid adoption into clinical trials underpinned by novel trial design. The results will help us treat the cause of disease not just their symptoms and help develop a new taxonomy of disease that moves away from a traditional “organ-based, speciality-focussed” approach to a process-driven, pathway-focussed classification for inflammatory diseases.
Latest news from the Kennedy Institute
27 November 2020
In a research letter to the British Journal of Surgery (BJS) a team of plastic surgeons reveal the effect of the COVID-19 pandemic on skin cancer surgery in the UK.
25 November 2020
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
13 November 2020
Professor Simon has been successful in her Wellcome Trust Investigator Award entitled: “Proteostasis and Autophagy in Immune Senescence.”
3 November 2020
NDORMS has been designated a EULAR Centre of Excellence 2020-2025, in recognition of our continued high-quality research publications in rheumatology.